Vantage logo

Big caps bounce back for biopharma

Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter.

Vantage logo

Your 2023 wildcard predictions revealed

Will biotech lead a bull market recovery? Will Novartis spin off its cell therapy business? Read on for some of your leftfield predictions for biopharma.

Vantage logo

Gilead goes long-acting in HIV

Sunlenca gets a US green light at the second time of asking, but combination success will be vital to it fulfilling its promise.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.